Yong K L, Linch D C
Department of Haematology, University College and Middlesex School of Medicine, London, United Kingdom.
J Immunol. 1993 Mar 15;150(6):2449-56.
The directed migration of neutrophils across vascular endothelium to localize in inflammatory tissues is controlled by soluble mediators, including cytokines and growth factors. Granulocyte-macrophage CSF (GM-CSF) enhances and primes neutrophil functions, but its specific role in the movement and localization of neutrophils to infective sites has not been clarified. We demonstrate, using an in vitro model of the vascular endothelial barrier, that GM-CSF enhances neutrophil migration across unstimulated endothelium, increasing the percentage of migrating cells from 7.7 +/- 0.9% (mean +/- SE) in controls to 12.5 +/- 1.5% in the presence of GM-CSF (100 ng/ml) (n = 14, p < 0.0005). This effect is dose dependent, with maximal effects achieved at concentrations of 10 ng/ml or greater, and is independent of concentration gradients of GM-CSF. Transendothelial migration of neutrophils can also be increased by cytokine treatment of the endothelial cells. Preincubation of endothelial monolayers with IL-1 (10 U/ml) for 4 h increases the percentage of migrating cells to 16.8 +/- 1.4% (238 +/- 25% of base line, n = 7, p < 0.005). In the presence of GM-CSF, however, neutrophil migration across IL-1 treated endothelium (12.5 +/- 1.6%, n = 7) is no different from that across resting endothelium (11.6 +/- 1.6% in the same seven experiments). Hence GM-CSF acts to inhibit neutrophil migration across IL-1-activated endothelium, and almost completely abolishes IL-1-induced migration (n = 7, p < 0.0005). This differential effect of GM-CSF on neutrophil migration, depending upon the conditions of endothelial activation, does not relate to an effect on adhesion, because GM-CSF has no effect on the increased adhesion of neutrophils to IL-1-treated endothelium. The effect of GM-CSF on neutrophil migration across activated endothelium may be relevant to the clinical administration of human rGM-CSF.
中性粒细胞穿过血管内皮向炎症组织定向迁移的过程受可溶性介质控制,这些介质包括细胞因子和生长因子。粒细胞-巨噬细胞集落刺激因子(GM-CSF)可增强并启动中性粒细胞的功能,但其在中性粒细胞向感染部位移动和定位中的具体作用尚未明确。我们使用血管内皮屏障的体外模型证明,GM-CSF可增强中性粒细胞穿过未受刺激的内皮的迁移能力,使迁移细胞的百分比从对照组的7.7±0.9%(平均值±标准误)增加到存在GM-CSF(100 ng/ml)时的12.5±1.5%(n = 14,p < 0.0005)。这种效应呈剂量依赖性,在浓度为10 ng/ml或更高时达到最大效应,且与GM-CSF的浓度梯度无关。对内皮细胞进行细胞因子处理也可增加中性粒细胞的跨内皮迁移。用IL-1(10 U/ml)预孵育内皮单层4小时可使迁移细胞的百分比增加到16.8±1.4%(为基线的238±25%,n = 7,p < 0.005)。然而,在存在GM-CSF的情况下,中性粒细胞穿过经IL-1处理的内皮的迁移率(12.5±1.6%,n = 7)与穿过静止内皮的迁移率(在相同的七个实验中为11.6±1.6%)没有差异。因此,GM-CSF可抑制中性粒细胞穿过IL-1激活的内皮的迁移,并几乎完全消除IL-1诱导的迁移(n = 7,p < 0.0005)。GM-CSF对中性粒细胞迁移的这种差异效应,取决于内皮激活的条件,与对黏附的影响无关,因为GM-CSF对中性粒细胞与经IL-1处理的内皮的黏附增加没有影响。GM-CSF对中性粒细胞穿过激活内皮的迁移的影响可能与重组人GM-CSF的临床应用有关。